New results from study of MM 398 in Gastric Cancer
Results of a Phase II study of 124 patients with advanced Oesophago-Gastric Cancer who had failed one prior chemotherapy regimen and were then treated with MM 398 (nanoliposomal encapsulated irinotecan), from Merrimack Pharmaceuticals, have been published in the Annals of Oncology. Patients were treated with either MM 398, irinotecan or docetaxel. Results show that the median progression-free survival (PFS) and overall survival were similar between the trial arms. Commonest grade 3�4 adverse event reported was diarrhoea in the PEP02 and irinotecan groups (27.3% versus 18.2%). The objective response rate associated with PEP02 was comparable with docetaxel and numerically greater than that of irinotecan.
See: "A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma" A. C. Roy et al. Ann Oncol (2013) 24 (6): 1567-1573. doi: 10.1093/annonc/mdt002
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins